Brainsway (BWAY) Stock: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$12.60
-0.60 (-4.55%)
▼
5d:
-4.62%
30d:
-11.7%
90d:
-17.05%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 10, 2026
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.67
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$15.32
17.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $12.60, which is considered oversold relative to its 30-day fair value range of $13.33 to $14.32. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.9) compared to its historical average (44.1). Remarkably, the market is currently pricing in an annual earnings decline of 17.4% over the next few years. This pessimistic expectation contrasts with the company's recent 64.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $12.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: BWAY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.27 (+52.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $12.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: BWAY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.27 (+52.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.33 -
$14.32
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 52.9% below Wall St target ($19.27)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.33 -
$14.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$12.50
Resistance Level
$14.38
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.87
Wall Street Target
$19.27
(+52.9%)
Revenue Growth (YoY)
35.4%
Earnings Growth (YoY)
64.6%
Profit Margin
15.6%
Valuation Discount vs History
-17.4% cheaper
PE vs Historical
24.9 vs 44.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.4%
(market-implied from PE analysis)
1-Year Target
$11.34
(-10%)
2-Year Target
$10.21
(-19%)
3-Year Target
$9.19
(-27%)
3-Yr Target (if PE normalizes)
(PE: 25→44)
$16.29
(+29%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.9, Growth: 65.2%)
$42.52
(+238%)
Base:
(SPY PE: 20.4, Growth: 65.2%)
$34.89
(+177%)
Bear:
(PE: 17.3, Growth: 65.2%)
$29.65
(+135%)
📈
Valuation based on Current Earnings
Forward PE: 17.92 | Forward EPS (Implied): $0.70
Bull Case
$15.21
(+21%)
Analyst growth 15.0%, PE expands to 18.8
Base Case
$12.60
(0%)
Market implied 0.0%, PE stable at 17.9
Bear Case
$9.64
(-24%)
Severe decline -15.0%, PE contracts to 16.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.9 to 44.1
Stabilization Target:
$22.35
(+77.3%)
PE Expansion Potential:
+77.3%
Share & Embed Analysis
Last updated: October 02, 2026 2:18 AM ET
Data refreshes hourly during market hours. Next update: 3:18 AM
Data refreshes hourly during market hours. Next update: 3:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
